Evidence map›Paper›PMID 35507282›Full record

ReviewCurrent topics in behavioral neurosciences2022

Current Pharmacological Treatments for ADHD.

Madeleine J Groom, Samuele Cortese

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current topics in behavioral neurosciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Attention-deficit hyperactivity disorder and oral health in children and adolescents: a systematic review.European archives of paediatric dentistry : official journal of the European Academy of Paediatric Dentistry · 2026
    Pooled it
  2. Add-OnNutrients · 2024
    Trial
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Plasma BDNF levels in children with ADHD before and after methylphenidate treatment.Scandinavian journal of child and adolescent psychiatry and psychology · 2026
    Article
  9. Article
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Article
  17. Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Madeleine J GroomAcademic Unit of Mental Health and Clinical Neurosciences, School of Medicine, Institute of Mental Health, University of Nottingham, Nottingham, UK. Maddie.Groom@nottingham.ac.uk.
Samuele CorteseFaculty of Environmental and Life Sciences, Center for Innovation in Mental Health, School of Psychology, University of Southampton, Southampton, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Attention-Deficit Hyperactivity Disorder (ADHD) is a prevalent neurodevelopmental condition associated with impaired function and increased risk of poor outcomes in children, young people and adults with the condition. Currently approved pharmacological treatments for ADHD include a range of stimulant (methylphenidate, amphetamine) and nonstimulant (atomoxetine, guanfacine, clonidine) medications. All have been shown to be effective in treating the symptoms of ADHD and improving other functional outcomes including quality of life, academic performance, rates of accidents and injuries, and do not appear to be associated with significant adverse outcomes or side effects. In this chapter, we review medications for ADHD by summarising the mechanisms of action of each of the two main classes of compounds (stimulants and nonstimulants), the formulations of the most commonly prescribed medications within each class, their efficacy in treating ADHD symptoms and other outcomes, and other factors that influence treatment decisions including side effects and tolerability, comorbidities and medical history. We conclude with a summary of the treatment decisions made by clinicians and suggest some next steps for research. Further research is needed to understand the mechanisms of action of these medications and how exactly they improve symptoms, and to examine their effects on commonly occurring comorbidities.

Indexed as

Attention Deficit Disorder with HyperactivityCentral Nervous System StimulantsDrug-Related Side Effects and Adverse ReactionsMethylphenidateAdolescentAdultAtomoxetine HydrochlorideChildHumansQuality of LifeAtomoxetine HydrochlorideCentral Nervous System StimulantsMethylphenidateADHDAmphetamineClonidineComorbidityEfficacyFunctional outcomesGuanfacineMethylphenidateNonstimulantStimulantTolerabilityTreatment

Identifiers

PMID35507282

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.